

INTRODUCTION

Hundreds of drugs are hepatotoxic. We know the mechanism of action on the liver only for few drugs. They attack this organ at different sites. The hepatotoxicity is produced through two mechanisms: **toxic metabolites** and **immunological reaction**. Indeed some drugs will continue to damage the liver after their suspension. Many drugs of every pharmacological group are involved. When a drug reaction is suspected, the literature of administered drug must be reviewed.

PATHOLOGY

Each drug produces different morphological and functional alterations and therefore different clinical manifestations. The morphologic lesions are:

-Hepatitis, acute, subacute and chronic, indistinguishable from viral hepatitis with hepatocellular necrosis, inflammation, cholestasis. It can be acute and sometimes hyperacute and fatal (fulminant) or it can be chronic with fibrosis and even cirrhosis. Observed with: **Amineptine, Nitrofurantoin, Phenybutazone, Quinidine, Sulphonamides**, and many more.

-Cholestasis without inflammation or necrosis. The cholestasis is intralobular, cytoplasmic and canalicular mostly of zone 3. It is attributed to impairment of bile secretion from the hepatocyte into the bile canaliculus for an acquired defect of the bile secretory apparatus of the hepatocyte similar to the congenital defect in Dubin-Johnson syndrome. The prognosis is good with suspension of the drug. Sometimes resumption of the drug after some time does not cause any more the cholestatic reaction.

Drugs involved: **Oral contraceptives, estrogens, anabolic steroids, Chlorpromazine**.

-Cholestasis with portal inflammation. Changes similar to previous cholestatic picture plus non-specific portal inflammation.

Observed with: **Captopril, Azothioprine, Chlorpromazine, Gold, Cyclosporine, Erythromycin, Penicillamine**.

-Cholangitis (affecting portal bile ducts) and **Cholangiolitis** (affecting portal bile ductules).

The mechanism is probably immunoallergic. There is epithelial degeneration of bile duct epithelium, neutrophilic infiltration in and around bile ducts or ductules, portal lymphocytic and eosinophilic reaction. The lesions are usually reversible with discontinuation of the drug but permanent rarefaction of bile ducts may result with some drugs with changes similar to primary biliary cirrhosis. Example: **Chlorpromazine**.

-Granulomatous hepatitis. These granulomas are always non-caseating, intralobular or portal or both. They may be clinically silent. They may produce elevation of serum alkaline phosphatase due to small multifocal parenchymal compressions affecting the bile flow.

Drugs involved: **Allopurinol, Aspirin, Diazepam, Isoniazide, Phenitoin, Sulphonamides**.

Steatosis, macrovesicular: Presence of single, large fat droplets in hepatocytes pushing the nucleus to the periphery of the cell, with or without necrosis (pyknosis). This change is probably due to impaired egress of lipid from hepatocyte. The cell cannot export any more its lipoproteins.

Drugs involved: **Glucocorticoids, Methotrexate, L-Asparaginase**.

Steatosis, microvesicular: presence of small fatty vesicles filling the cytoplasm of the hepatocyte (foamy hepatocyte). The nucleus is in the center of the cell. The lesion is attributed to interference with oxidation of fatty acids by mitochondria. Very serious lesion. Seen in azotemia, pancreatitis and acute steatosis of pregnancy. Some responsible drugs are: **Tetracycline, Pirprophen, Amineptin, Valproate**.

Phospholipidosis: there are foamy hepatocytes plus, under electron microscopy, large lysosomal inclusions composed of densely packed concentric membranes with a fingerprinting pattern. There is also reduction of the cristae in the mitochondria and vesicles in the smooth ER. The lesion was recognized by Oda in Japan in 1969. Later, in 1975, it was recognized by Lullman et al in inborn errors of phospholipid metabolism. Drugs responsible: **Colargil** (Oda et al. 1969), **Amiodarone** (Pousell et al. 1984).

-Vascular lesions: venous thromboses, necrotizing angiitis, arterial intimal hyperplasia, perisinusoidal fibrosis (Vit.A), sinusoidal dilatation, peliosis, veno-occlusive disease, Budd-Chiari syndrome, hepatoportal sclerosis, nodular hyperplasia of the liver.

Drugs: **Immunosuppressive drugs, oral contraceptives, testosterone**.

-Hepatic tumors: hepatocellular adenoma and carcinoma, cholangiocarcinoma, angiosarcoma, hemangioendothelioma.
 Drugs: **Anabolic and contraceptives drugs, Vinyl Chloride.**

EXAMPLES

HALOTHANE HEPATITIS

[Click on picture to enlarge](#)

Case History

Forty four year old lady had uterine curettage for metrorrhagia. Eight weeks later she had hysterectomy. Three days after hysterectomy she became jaundiced. Seven days later she died in liver failure. Halothane was used as anesthetic in both surgical procedures. The autopsy showed massive liver necrosis. It appears that the liver damage was mediated by an immunoreactive mechanism. Multiple exposures increase the incidence of liver damage.



Fig.8-4-1:Fulminant halothane Hepatitis.

The liver is flabby, soft, friable similar to any acute viral hepatitis. It was called in the past "acute yellow atrophy".




Fig.8-4-28-4-2. Histology of the same case.

Massive centrilobular necrosis. Notice the central vein and necrosis of liver cells in all three zones of the lobule. A few clusters of hepatocytes in form of cords and pseudo-ductules remain in the periphery of the lobule. Notice absence of inflammatory reaction and no endophlebitis of the vein as it would be seen in viral hepatitis.




Fig. 8-4-3. Chlorpromazine (Thorazine)

With this drug 1% of patients are susceptible to develop jaundice which appears after 1-5 weeks of treatment. The hepatic damage consists of cytoplasmic and canalicular cholestasis and with only portal inflammation with eosinophils. Cytonecrosis is minimal. Prognosis is good. Notice the presence of fine yellow granular bile pigment in the cytoplasm of hepatocytes around the central vein (zone 3).

AMIODARONE HEPATITIS

[Click on picture to enlarge](#)

This drug may cause damage of the liver together with thyroid dysfunction, pulmonary fibrosis, neuropathy, skin discoloration, ecchymoses and corneal deposits. The toxicity is dose related and occurs with more than 200mg daily. The changes in the liver consist of phospholipidosis and alcoholic-like changes with Mallory bodies in periportal hepatocytes and late periportal fibrosis. The accumulation of amiodarone in the liver can be assessed by computerized tomography because of the high iodine content of the drug. Its iodine is responsible for the thyroid dysfunction. Mild increase of serum transaminases are seen in 15 to 55% of patients




Fig. 8-4-4 Amiodarone hepatitis

54 year old male taking amiodarone for many years developed clinical hepatitis: ALT 780, AST 339. This slide demonstrates hydropic swelling of hepatocytes, focal cell necrosis with inflammatory reaction and cytoplasmic cholestasis. The [Review of Pathology of the Liver:Table of Contents](#) foamy appearance is due to **phospholipidosis** present practically in every case and is due to accumulation of sphingomyelin in hepatocytes. (see Em Picture below).




Fig.8-4-5. This drug produces also Mallory bodies in the periportal area. The common location of Mallory bodies in alcoholic hepatitis is the central lobular area. These alcohol-like alterations are uncommon but they may continue to progress after discontinuation of the drug for many months




Fig.8-4-6.

In this case, there is beginning portal, periportal and porto-central fibrosis. The case is longstanding, more than 8 years under amiodarone treatment.




Fig. 8-4-15:
Mallory bodies




Fig. 8-4-16:
Giant Mitochondria




Fig. 8-4-17:
Myelin figures

Phenytoin (Dilantin)

This anticonvulsant drug which commonly causes lymphadenopathy, polyarteritis nodosa and bone marrow damage more rarely causes clinical hepatitis. Here it can cause cholestasis multifocal necrosis, lymphocyte "beading" in sinusoids similar to infectious mononucleosis but more commonly it causes **multiple histiocytic granulomas** which cause high elevation of serum alkaline phosphatase.




Fig. 8-4-7. Dilantin hepatitis.

This slide shows cytoplasmic cholestasis and sinusoidal beading of lymphocytes similar to a mild case of infectious mononucleosis




Fig. 8-4-8. Same case.

Presence of a large Histiocytic granuloma, sharply demarcated, without necrosis.

These histiocytic nodules act as many small space-occupying lesions which compress the surrounding liver parenchyma affecting the bile flow thus producing retention of enzymes normally eliminated in the bile such as alkaline phosphatase

METHOTREXATE

Methotrexate

The changes produced by this drug in the liver, in order of progressive severity, are: **steatosis, ballooning**

degeneration, cell necrosis, nuclear changes, cholestasis, Ito cell hyperplasia, portal inflammation, progressive fibrosis, cirrhosis.

Liver damage is directly related to **DURATION** of therapy and inversely related to the **LENGTH OF INTERVALS** between doses. Daily small doses are more dangerous than weekly large doses. The treatment must be monitored with repeat liver biopsies. There are no good alternatives to liver biopsies. Biochemical tests are insufficient for assessing the hepatic injury.




Fig. 8-4-9. Methotrexate hepatitis.
This is the earliest lesion. There are foci of macrovesicular steatosis.




Fig. 8-4-10. Another case, advanced lesion.
In this case the lesion is more advanced: there is ballooning degeneration, cell necrosis, nuclear changes, fine cholestasis and beginning fibrosis,




Fig. 8-4-11. Another case, Late lesion.
Besides the above illustrated cellular changes, in this case there is fibrosis, portal, periportal and porto-portal in some areas.

IV TETRACYCLINE CAUSING MICROVESICULAR STEATOSIS




Fig. 8-4-12. Microvesicular steatosis, due to IV tetracycline
Small fatty droplets, perinuclear, are filling the hepatocytes and imparting a foamy appearance to these cells. There is no cell necrosis and no inflammatory reaction. Microvesicular steatosis similar to that induced by IV tetracycline occurs in acute fatty liver of pregnancy.

GRANULOMATOUS HEPATITIS




Fig. 8-4-13. Granulomatous hepatitis.
This slide is from a patient treated with sulpha drugs. There is an intralobular histiocytic granuloma, non-caseating.

VENO-OCCLUSIVE DISEASE




Fig. 8-4-14. Veno-Occlusive Disease (VOD).

Obliteration of a central vein in a case of immunosuppressive therapy for bone marrow transplant. The obliteration occurs by endovascular fibrosis which is not the result of an organized thrombus but the result of occlusive vascular fibrosis similar to that fib occurring in the closure of the ductus arteriosus immediately and due to reduction of the blood flow.

CONTENTS
